Follow on Google News News By Tag * Pharmacogenomics Testing * Molecular Testing * Automated Microarray Platform * Sample To Result Automation * Hepatitis C virus testing * More Tags... Industry News News By Place Country(s) Industry News
Follow on Google News | AutoGenomics to Introduce INFINITI SMART – Sample-to-Result NextGen Automation Platform at AACCINFINITI® SMART is a fully automated “walk-away” The addition of the INFINITI® SMART to the existing AutoGenomics’ AutoGenomics expects to initially offer a menu of 11 tests with the INFINITI® SMART including pharmacogenomics tests for CYP2D6, 2C19, 2C9-VKORC1, 3A4, 3A5, Apo E, Factor II, Factor V, MTHFR, Flu and HCV genotyping. AutoGenomics intends to obtain FDA 510(k) clearance for these tests. “By offering total automation and eliminating the need for instrumentation such as sample extraction units and thermocyclers, we are focusing on meeting key customer needs to lower the cost per reportable result and enhance productivity in the lab,” said Fareed Kureshy, President and Chief Executive Officer of AutoGenomics. About AutoGenomics AutoGenomics Inc., a privately held company based in Vista, CA, developed the first automated, microarray based multiplexing diagnostic platform that can be used to assess disease signatures with novel genomic and proteomic markers in the area of pharmacogenomics, genetic disorders, infectious disease and cancer. With the discovery of genes and their link to various disease states, the platform has the versatility to revolutionize the way patients are diagnosed, monitored and managed, leading to the era of precision medicine. www.autogenomics.com. End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|